190 related articles for article (PubMed ID: 37430416)
1. Children's Oncology Group's 2023 blueprint for research: Behavioral science.
Embry L; Bingen K; Conklin HM; Hardy S; Jacola LM; Marchak JG; Paltin I; Pelletier W; Devine KA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30557. PubMed ID: 37430416
[TBL] [Abstract][Full Text] [Related]
2. Children's Oncology Group's 2013 blueprint for research: behavioral science.
Noll RB; Patel SK; Embry L; Hardy KK; Pelletier W; Annett RD; Patenaude A; Lown EA; Sands SA; Barakat LP;
Pediatr Blood Cancer; 2013 Jun; 60(6):1048-54. PubMed ID: 23255478
[TBL] [Abstract][Full Text] [Related]
3. Children's Oncology Group's 2023 blueprint for research: Cancer control and supportive care.
Esbenshade AJ; Sung L; Brackett J; Dupuis LL; Fisher BT; Grimes A; Miller TP; Ullrich NJ; Dvorak CC;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30568. PubMed ID: 37430431
[TBL] [Abstract][Full Text] [Related]
4. Children's Oncology Group's 2023 blueprint for research: Diversity and health disparities.
Winestone LE; Beauchemin MP; Bona K; Kahn J; Prasad P; Robles JM; Velez MC;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30592. PubMed ID: 37501542
[TBL] [Abstract][Full Text] [Related]
5. Children's Oncology Group 2023 blueprint for research: Adolescent and young adult oncology.
Roth ME; Grimes AC; Reed DR; Weiss AR; Mittal N; Parsons SK; Freyer DR;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30564. PubMed ID: 37439574
[TBL] [Abstract][Full Text] [Related]
6. Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.
Freyer DR; Felgenhauer J; Perentesis J;
Pediatr Blood Cancer; 2013 Jun; 60(6):1055-8. PubMed ID: 23424167
[TBL] [Abstract][Full Text] [Related]
7. Children's Oncology Group's 2023 blueprint for research: Germ cell tumors.
Bhuta R; Shah R; Gell JJ; Poynter JN; Bagrodia A; Dicken BJ; Pashankar F; Frazier AL; Shaikh F
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30562. PubMed ID: 37449938
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Children's Oncology Group's 2023 blueprint for research: Young investigators.
Esbenshade AJ; Kahalley LS; Wistinghausen B; Cash T; Baertschiger RM; Zarnegar-Lumley S; Green A; Dhall G;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30567. PubMed ID: 37438856
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
11. Children's Oncology Group's 2013 blueprint for research: survivorship and outcomes.
Armenian SH; Landier W; Hudson MM; Robison LL; Bhatia S;
Pediatr Blood Cancer; 2013 Jun; 60(6):1063-8. PubMed ID: 23255494
[TBL] [Abstract][Full Text] [Related]
12. Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care.
Sung L; Zaoutis T; Ullrich NJ; Johnston D; Dupuis L; Ladas E;
Pediatr Blood Cancer; 2013 Jun; 60(6):1027-30. PubMed ID: 23255159
[TBL] [Abstract][Full Text] [Related]
13. Children's Oncology Group 2023 blueprint: Nursing discipline.
Zupanec S; Herriage T; Landier W;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30575. PubMed ID: 37470719
[TBL] [Abstract][Full Text] [Related]
14. Children's Oncology Group's 2023 blueprint for research: Epidemiology.
Lupo PJ; Marcotte EL; Scheurer ME; Poynter JN; Spector LG;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30566. PubMed ID: 37449937
[TBL] [Abstract][Full Text] [Related]
15. Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
Bagatell R; DuBois SG; Naranjo A; Belle J; Goldsmith KC; Park JR; Irwin MS;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30572. PubMed ID: 37458162
[TBL] [Abstract][Full Text] [Related]
16. Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine Workshop highlights and next steps.
Kirch R; Reaman G; Feudtner C; Wiener L; Schwartz LA; Sung L; Wolfe J
CA Cancer J Clin; 2016 Sep; 66(5):398-407. PubMed ID: 27145249
[TBL] [Abstract][Full Text] [Related]
17. Cancer survivorship practices, services, and delivery: a report from the Children's Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committees.
Eshelman-Kent D; Kinahan KE; Hobbie W; Landier W; Teal S; Friedman D; Nagarajan R; Freyer DR
J Cancer Surviv; 2011 Dec; 5(4):345-57. PubMed ID: 21894490
[TBL] [Abstract][Full Text] [Related]
18. Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics.
Fox E; Parsons DW; Weigel BJ;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30563. PubMed ID: 37430453
[TBL] [Abstract][Full Text] [Related]
19. Children's Oncology Group's 2023 blueprint for research: Pharmacy.
Ostrenga AR; Thackray J; McLearan HH; Mulieri KM; Bisaccia E; Militano O; Dupuis LL; Bernhardt MB;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30581. PubMed ID: 37460409
[TBL] [Abstract][Full Text] [Related]
20. The integration of psychology in pediatric oncology research and practice: collaboration to improve care and outcomes for children and families.
Kazak AE; Noll RB
Am Psychol; 2015; 70(2):146-58. PubMed ID: 25730721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
